Step 1: Select the episodes & 1-minute challenges you'd like to consume
Step 2: Bank time as you blaze your way through the program
Step 3: Claim credit once available as shown in the Progress Bar
Step 4: Track the status of credits claimed in your profile
To experience MinuteCE for yourself, select one of the episodes below to start learning!
What Are the Data for HER2-Targeted ADCs in HR+/HER2-Low Metastatic Breast Cancer?
What Are the Data for HER2-Targeted ADCs in HR+/HER2-Low Metastatic Breast Cancer?
Who Is the Best Candidate for Sequencing Trastuzumab Detruxtecan (T-DXd) First?
Who Is the Best Candidate for Sequencing Trastuzumab Detruxtecan (T-DXd) First?
Adjuvant Treatment for BRAF+ Stage III Melanoma: A Case Study to Weigh ICI Versus Targeted Therapies
Adjuvant Treatment for BRAF+ Stage III Melanoma: A Case Study to Weigh ICI Versus Targeted Therapies
How Can We Best Manage irAEs During Adjuvant ICIs for Melanoma? A Case-Based Approach
How Can We Best Manage irAEs During Adjuvant ICIs for Melanoma? A Case-Based Approach
What Are the Data for TROP2-Targeted ADCs in HR+/HER2-Positive and HER2-Low MBC?
What Are the Data for TROP2-Targeted ADCs in HR+/HER2-Positive and HER2-Low MBC?
What Are the Clinical and Therapeutic Implications of the Evolving HER2 Testing Landscape?
What Are the Clinical and Therapeutic Implications of the Evolving HER2 Testing Landscape?
Monitoring and Managing Adverse Effects With ADCs in HR+ Breast Cancer: Strategies To Improve Outcomes
Monitoring and Managing Adverse Effects With ADCs in HR+ Breast Cancer: Strategies To Improve Outcomes
Optimizing Adjuvant Treatment for Stage IV Melanoma Patients Rendered NED After Surgery
Optimizing Adjuvant Treatment for Stage IV Melanoma Patients Rendered NED After Surgery
Questions and Conundrums: What Is the Future of ADCs in HR+/HER2-Low MBC?
Questions and Conundrums: What Is the Future of ADCs in HR+/HER2-Low MBC?
How Do Brain Metastases Affect Your Choice of Systemic Treatment in a Patient with HR+/HER2-low MBC?
How Do Brain Metastases Affect Your Choice of Systemic Treatment in a Patient with HR+/HER2-low MBC?
Selection and Sequencing of ADCs in HR+/HER2-Low MBC
Selection and Sequencing of ADCs in HR+/HER2-Low MBC
Who Is the Best Candidate for Sequencing Sacituzumab Govitecan Before T-DXd in HR+ Breast Cancer?
Who Is the Best Candidate for Sequencing Sacituzumab Govitecan Before T-DXd in HR+ Breast Cancer?
Which Resected Stage II Melanoma Patients Benefit from Adjuvant ICI Therapy?
Which Resected Stage II Melanoma Patients Benefit from Adjuvant ICI Therapy?
How Do Patient Characteristics Impact Adjuvant Therapy in All Stages of Resectable Melanoma?
How Do Patient Characteristics Impact Adjuvant Therapy in All Stages of Resectable Melanoma?